Literature DB >> 18279810

Activated leukocyte cell adhesion molecule: a new paradox in cancer.

Solomon F Ofori-Acquah1, Judy A King.   

Abstract

The activated leukocyte cell adhesion molecule [ALCAM/CD166/melanoma metastasis clone D (MEMD)] is an immunoglobulin superfamily cell adhesion molecule. It is expressed developmentally in cells of all 3 embryonic lineages. The ALCAM expression is limited to subsets of cells in most adult tissues. ALCAM is localized at intercellular junctions in epithelium presumably as part of the adhesive complex that maintains tissue architecture. Over the past decade, alterations in expression of ALCAM have been reported in several human tumors (melanoma, prostate cancer, breast cancer, colorectal carcinoma, bladder cancer, and esophageal squamous cell carcinoma). This review summarizes the current knowledge of the role of ALCAM in malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18279810     DOI: 10.1016/j.trsl.2007.09.006

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  59 in total

1.  CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.

Authors:  Noriyuki Kijima; Naoki Hosen; Naoki Kagawa; Naoya Hashimoto; Akiko Nakano; Yasunori Fujimoto; Manabu Kinoshita; Haruo Sugiyama; Toshiki Yoshimine
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Alcama mediates Edn1 signaling during zebrafish cartilage morphogenesis.

Authors:  Priya Choudhry; Deepa Joshi; Birgit Funke; Nikolaus Trede
Journal:  Dev Biol       Date:  2010-11-10       Impact factor: 3.582

3.  Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells.

Authors:  Barbara Sobotič; Matej Vizovišek; Robert Vidmar; Petra Van Damme; Vasilena Gocheva; Johanna A Joyce; Kris Gevaert; Vito Turk; Boris Turk; Marko Fonović
Journal:  Mol Cell Proteomics       Date:  2015-06-16       Impact factor: 5.911

4.  Hierarchical organization of osteoblasts reveals the significant role of CD166 in hematopoietic stem cell maintenance and function.

Authors:  Brahmananda R Chitteti; Ying-Hua Cheng; Melissa A Kacena; Edward F Srour
Journal:  Bone       Date:  2013-01-28       Impact factor: 4.398

5.  Stable isotope labeling in zebrafish allows in vivo monitoring of cardiac morphogenesis.

Authors:  Anne Konzer; Aaron Ruhs; Helene Braun; Benno Jungblut; Thomas Braun; Marcus Krüger
Journal:  Mol Cell Proteomics       Date:  2013-02-14       Impact factor: 5.911

6.  Characterization and functionality of proliferative human Sertoli cells.

Authors:  Kitty Chui; Alpa Trivedi; C Yan Cheng; Diana B Cherbavaz; Paul F Dazin; Ai Lam Thu Huynh; James B Mitchell; Gabriel A Rabinovich; Linda J Noble-Haeusslein; Constance M John
Journal:  Cell Transplant       Date:  2010-11-05       Impact factor: 4.064

7.  ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9.

Authors:  Alvaro Gilsanz; Lorena Sánchez-Martín; María Dolores Gutiérrez-López; Susana Ovalle; Yesenia Machado-Pineda; Raquel Reyes; Guido W Swart; Carl G Figdor; Esther M Lafuente; Carlos Cabañas
Journal:  Cell Mol Life Sci       Date:  2012-09-30       Impact factor: 9.261

8.  Generation of novel monoclonal antibodies for the enrichment and characterization of human corneal endothelial cells (hCENC) necessary for the treatment of corneal endothelial blindness.

Authors:  Vanessa Ding; Angela Chin; Gary Peh; Jodhbir S Mehta; Andre Choo
Journal:  MAbs       Date:  2014       Impact factor: 5.857

9.  Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.

Authors:  Richard Tavaré; Wei H Wu; Kirstin A Zettlitz; Felix B Salazar; Katelyn E McCabe; James D Marks; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2014-08-04       Impact factor: 1.650

10.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Authors:  Merete Thune Wiiger; Hege B Gehrken; Øystein Fodstad; Gunhild M Maelandsmo; Yvonne Andersson
Journal:  Cancer Immunol Immunother       Date:  2010-07-16       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.